Background: Conflicting results currently exist on the effects of LDL-C levels and statins therapy on coronary atherosclerotic plaque, and the target level of LDL-C resulting in the regression of the coronary atherosclerotic plaques has not been settled.
Background
It is universally accepted that high serum concentrations of low-density lipoprotein cholesterol (LDL-C) can lead to atherosclerosis and accelerate the progression of atherosclerosis which is main causes of coronary artery disease [1] . Disruption of coronary atherosclerotic plaque (CAP) with subsequent thrombus formation may lead to sudden cardiac death, acute myocardial infarction, or unstable angina [2] . The evidence showed that reducing LDL-C can prevent coronary heart disease (CHD) and improve survival of CHD based on results from multiple randomized controlled trials (RCTs) [3, 4] .
For many years coronary angiography (CAG) has been the gold standard method for the investigation of the anatomy of coronary arteries and measure the efficacy of anti-atherosclerotic drug therapies [5, 6] . But changes in CAG are measured only in the vascular lumen and not in the vessel wall [7] , where the atherosclerotic process is located. Intravascular ultrasound (IVUS) is superior to angiography in the detection of early plaque formation and changes in plaque volume [8] [9] [10] . Through IVUS, Takagi et al. found that pravastatin lowered serum cholesterol levels and reduced the progression of CAP in patients with elevated serum cholesterol levels in 1997 [11] . Since then, multiple RCTs and no RCT about the effect of lowering LDL-C therapy on the regression of coronary atherosclerosis have been performed [12] [13] [14] [15] [16] . But the results varied with the RCTs: intensive LDL-C lowering therapy could reduce the progression of the plaques [12] ; the mild LDL-C lowering did not [14] [15] [16] . The meta-analysis by Bedi et al. [17] evaluated the effects of LDL-C lowering on CAP by comparing statins with control therapy, and demonstrated that treatment with statins could slow atherosclerotic plaque progression and lead to plaque regression. The meta-analysis by Tian et al. [18] showed that CAP could be regressed in group of patients with <100 mg of LDL-C level at follow up. But so far, there are no systematic reviews of the effects of LDL-C levels on CAP, and the targets of LDL-C level that could result in the regression of the plaques have not been settled.
In this study, we conducted meta-analyses to summarize findings from the current trials on LDL-C lowering therapy retarding the progression of the CAP and to identify the targets of LDL-C resulting in the regression of the CAP for guiding the LDL-C lowering therapy. Effect of different statins on the progression of the CAP was also investigated.
Methods

Search strategy and selection criteria
An electronic literature search was performed to identify all relevant studies published in PubMed, EMBASE, and Cochrane databases in the English language from Jan. 1, 2000 to Jan. 1, 2014, using the terms "atherosclerosis" and "cholesterol blood level". The references of the studies were also searched for relevant studies. Studies were included using the following criteria: 1) randomized controlled or prospective, blinded end-points trials in which patients with CHD were assigned to LDL-C lowering therapy or placebo, and its primary end point was CAP change detected by IVUS; 2) report of LDL-C levels at baseline and follow-up (in each arm) or the level of LDL-C which can be calculated from the data in the paper (as in the trial by Yokoyama M [15] , in which the LDL-C concentrations in control arm were directly extracted from the figure); 3) data on the volume of CAP, detected in IVUS at baseline and follow-up (in each arm), and volume of CAP was calculated as vessel volume minus lumen volume; Exclusion criteria were: 1) only CAP area or volume index or percent atheroma volume were detected by IVUS; 2) the levels of LDL-C at baseline or follow-up were not provided; and 3) target plaques were unstable.
Data extraction and quality assessment
Two investigators independently reviewed all potentially eligible studies and collected data on patient and study characteristics (author, year, design, sample size, the measures of LDL-C lowering, LDL-C levels, follow-up duration, and plaque volume), and any disagreement was resolved by consensus. The primary end point of this study was progression or regression of CAP detected by IVUS. Quality assessments were evaluated with Jadad quality scale [19] .
Data synthesis and analysis
Continuous variables (change of CAP volume from baseline to follow-up) were analyzed using standardized mean differences (SMD).
The trials may have control arm and multiple active treatment arms, changes of plaque volume in every arms were used for pooled analysis. According to the levels and the reducing percentage of LDL-C at follow-up, the arms were grouped to following groups: ≤70, >70 ≤ 100HP (>70 ≤ 100 mg and reducing percentage ≥30%), >70 ≤ 100MP (>70 ≤ 100 mg and reducing percentage ≥0 < 30%), >70 ≤ 100LP (>70 ≤ 100 mg and reducing percentage <0%), >100 mg/dL; and <0, ≥0 < 30, ≥30 < 40, ≥40 < 50, ≥50% respectively, to investigate the effect of different levels of LDL-C at follow up on CAPs. According to different statins, the arms were grouped to following groups: rosuvastatin, atorvastatin , pitavastatin, simvastatin, fluvastatin and pravastatin group, to investigate the effect of different statins on CAPs. The volume of CAP at follow up was compared with that at baseline to evaluate effect of LDL-C levels on regression of CAP.
Heterogeneity across trials (arms) was assessed via a standard χ 2 test with significance being set at p < 0.10 and also assessed by means of I 2 statistic with significance being set at I 2 > 50%. Pooled analyses were calculated using fixed-effect models, whereas random-effect models were applied in case of significant heterogeneity across studies (arms). Sensitivity analyses (exclusion of one study at one time) were performed to determine the stability of the overall effects of LDL-C levels. Additionally, publication bias was assessed using the Egger regression asymmetry test. Mean LDL-C level and follow up duration of groups were calculated by descriptive statistics. A two-sided p values < 0.05 was considered statistically significant. Statistical analyses were performed using STATA software 12.0 (StataCorp, College Station, Texas) and Review Manager V5.2 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012).
Results
Eligible studies
The flow of selecting studies for the meta-analysis is shown in Figure 1 . Briefly, of the initial 647 articles, one hundred and twenty of abstracts were reviewed, resulting in exclusion of 100 articles, and 20 articles were reviewed in full text, resulting in exclusion of 10 trials and inclusion of 18 additional trials. Twenty two RCTs [12] [13] [14] [15] [16] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , [32] [33] [34] [35] [36] and six blinded end-points trial [37] [38] [39] [40] [41] [42] were carefully evaluated. Five trials were excluded because of specific the index of plaque (volume index in TRUTH [24] , trial by Kovarnik T [31] , by Hattori K [42] , and by Petronio AS [32] ; area in LACMART [38] ); GAIN [20] [22], ILLUSTRATE [23] , JAPAN-ACS [12] , REACH [26] , SATURN [28] , ARTMAP [29] , ERASE [34] , STRADIVAR-IUS [35] , PERISCOPE [36] , and trials by Yokoyama M [15] , by Kawasaki M [16] , by Hong MK [27] , and Tani S [33] ) and four blinded end-points trial (ASTEROID [37] , COSMOS [40] , trial by Jensen LO [39] and trial by Nasu K [41] ) were finally analyzed. The characteristics of the included trials were shown in Table 1 . Among the 20 trials, there were 15 trials assessing statins (statin vs. usual care in 6 trials [14] [15] [16] 26, 33, 41] ; intensive statin vs. moderate statin treatment in 5 trials [12, 13, [27] [28] [29] ; follow up vs baseline in 3 trial [37, 39, 40] , before acute coronary syndrome (ACS) vs after ACS in one trial [34] ), 2 trials assessing enzyme acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibition (vs. placebo, both on the basis of mean LDL-C < 102 after background lipid-lowering therapy with statins in 62-79% of patients) [21, 22] , one trial assessing cholesteryl ester transfer protein (CETP) inhibitor torcetrapib (vs. statins on the basis of LDL-C ≤ 100 by statins) [23] , one trial assessing a decreasing obesity drug: rimonabant (vs. placebo, on the basis of statins therapy) [35] , and one trial assessing glucoselowering agents (pioglitazone vs glimepiride on the basis of statins therapy) [36] . In three trials [12, 14, 34] with acute coronary syndrome, all target plaques were selected in non-culprit vessels. Overall, 5910 patients with CHD underwent serial IVUS examination for evaluating regression of CAP. Follow-up periods ranged from 2 to 24 months. The levels of LDL-C of each arm at baseline and follow-up were shown in Table 2 .
Risk of bias of included studies, evaluated through Cochrane's methods, showed an overall acceptable quality of selected trials (Figures 2 and 3 ).
The effect of the levels of LDL-C at follow-up on regression of coronary atherosclerotic plaque LDL-C lowering in group ≤70 and >70 ≤ 100HP mg/dL could lead to regression of CAP, but LDL-C lowering in group >70 ≤ 100MP, >70 ≤ 100LP and >100 mg/dL could not ( Figure 4 , Table 3 ).
In group ≤70 mg/dL (including seven arms) with mean 18.6 months of follow up and group >70 ≤ 100HP mg/dL (including eleven arms) with mean 17.4 months of follow up, the volumes of CAP (125.9, 123.8 mm 3 respectively) at follow up were significantly decreased, compared with the volumes (177.1, 129.7 mm 3 respectively) at baseline [SMD −0.156 mm 3 , 95% CI (confidence interval) -0.235~−0.078, p = 0.000; SMD −0.123 mm 3 , 95% CI −0.199~−0.048, p = 0.001; respectively]. There was no significant heterogeneity among arms (χ 2 for heterogeneity = 0.57, p =0.997, I 2 = 0% for group ≤70 mg/dL; χ 2 for heterogeneity = 6.83, p =0.741, I 2 = 0% for group >70 ≤ 100HP mg/dL).
Sensitivity analyses suggested that LDL-C lowering in group ≤70 and >70 ≤ 100HP mg/dL could lead to regression of CAP with reduction of the CAP volume ranged from −0.146 mm 3 (SMD, 95% CI: −0.238~−0.054) when the arm of 2006 ASTEROID Ros was omitted to −0.167 mm 3 (SMD, 95% CI: −0.270~−0.064) when the arm of 2011 SATURN Ros was omitted; and from −0.103 mm 3 (SMD, 95% CI: −0.182~−0.024) when the arm of 2009 JAPAN-ACS Ato was omitted to −0.151 mm 3 (SMD, 95% CI: −0.235~−0.067) when the arm of 2004 REVERSAL Ato was omitted. No publication bias was found, the values of p by Egger's test for group ≤70 and >70 ≤ 100HP mg/dL were 0.835, 0.501 respectively.
In group >100 mg/dL (including eleven arms) with mean 14.6 months of follow up, the volume of CAP at follow up was not significantly increased, compared with the volumes at baseline (SMD 0.013 mm 3 , 95% CI −0.0920
.118, p = 0.809). There was no significant heterogeneity among arms (χ 2 for heterogeneity = 2.49, p =0.991, I 2 = 0%). Sensitivity analyses suggested that LDL-C lowering to >100 mg/dL at follow-up could still not lead to regression of CAP with reduction of the plaque volume ranged from −0.005 mm 3 (95% CI −0.136~0.126) when the arm of 2004 REVERSAL Pro was omitted to 0.034 mm 3 (SMD, 95% CI −0.075~0.143) when 2005 Tani S Pra was omitted. No publication bias was observed from the values of p (0.566) by Egger's test.
Mean levels of LDL-C at baseline and follow up and mean reducing percentage of LDL-C in group ≤70, >70 ≤ 100HP, >70 ≤ 100MP, >70 ≤ 100LP and >100 mg/dL were showed in Table 4 .
The effect of the LDL-C reducing percentage at follow-up on regression of CAP LDL-C lowering in group ≥30 < 40, ≥40 < 50, ≥50% could lead to regression of CAP, but LDL-C lowering in group <0 and ≥0 < 30% could not ( Figure 5 , Table 3 ).
In group ≥30 < 40% (including ten arms) with mean 10.3 months of follow up, and group ≥40 < 50% (including eight arms) with mean 19.4 months of follow up, the volumes of CAP (94.3, 150.7 mm 3 respectively) at follow up were significantly decreased, compared with the volumes (102.9, 157.8 mm 3 respectively) at baseline (SMD −0.199 mm 3 , 95% CI −0.314~−0.085, p = 0.001; SMD −0.108 mm 3 , 95% CI −0.176~−0.040, p = 0.002; respectively). There was no significant heterogeneity among arms (χ 2 for heterogeneity = 3.10, P = 0.960, I 2 = 0%; χ 2 for heterogeneity = 2.50, p =0.927, I 2 = 0%; for group ≥30 < 40, and group ≥40 < 50 respectively).
Sensitivity analyses showed that LDL-C lowering in group ≥30 < 40% and group ≥40 < 50 could still lead to regression of CAP with reduction of the plaque volume ranged from −0.166 mm 3 (95% CI −0.295~−0.038) when the arm of 2009 JAPAN-ACS Ato was omitted Note: *calculated on the bases of baseline levels and change percentage at follow up [21] . # calculated according to Figure 2 in the paper [15] . In group <0 with mean 19.6 months of follow up and group ≥0 < 30% with mean 18.3 months of follow up, the volume of CAP at follow up was not significantly decreased, compared with the volumes at baseline (SMD −0.034 mm 3 , 95% CI −0.111~0.044, p = 0.396; SMD −0.032 mm 3 , 95% CI −0.093~0.030, p = 0.315 respectively). There was no significant heterogeneity among arms (χ 2 for heterogeneity = 1.55, p =0.981, I 2 = 0% for group <0%; χ 2 for heterogeneity = 4.59, p =0.970, I 2 = 0% for group ≥0 < 30%).
Sensitivity analyses showed that LDL-C lowering in group ≥0 < 30% could not still significantly decrease the volume of CAP with reduction of the CAP volume ranged from −0.010 mm 3 (SMD, 95% CI: −0.080~0.061) when the arm of 2007 ILLUSTRATE Ato + Tor was omitted to −0.042 mm 3 (SMD, 95% CI: −0.108~0.024) when the arm of 2004 REVERSAL Pro was omitted. No publication bias was found, the values of p by Egger's test for group ≥0 < 30% were 0.537.
Mean levels of LDL-C at baseline and follow up, mean reducing percentage of LDL-C in group <0, ≥0 < 30, ≥30 < 40, ≥40 < 50 and ≥50%, were showed in Table 4 .
The effect of lowering LDL-C by statins on regression of coronary atherosclerotic plaque
LDL-C lowering by rosuvastatin, atorvastatin and pitavastatin in group ≤70 and >70 ≤ 100HP mg/dL could lead to regression of CAP, but LDL-C lowering by simvastatin, fluvastatin and pravastatin could not ( Figure 6 , Table 5 ).
LDL-C lowering by rosuvastatin (mean 33.3 mg daily for mean 20 months), atorvastatin (mean 60.3 mg daily for mean 17 months) and pitavastatin (4 mg daily for 81 2 months) in group ≤70 and >70 ≤ 100HP mg/dL could significantly decrease the volumes of CAP at follow up, compared with the volumes at baseline (SMD −0.162 mm 3 , 95% CI: −0.234~−0.081, p = 0.000; SMD −0.101, 95% CI: −0.184~−0.019, p = 0.016; SMD −0.304 mm 3 , 95% CI: −0.553~−0.055, p = 0.017; respectively). There was no significant heterogeneity among arms (χ 2 for heterogeneity = 0.37, p =0.985, I 2 = 0% for rosuvastatin; χ 2 for heterogeneity = 4.44, p =0.728, I 2 = 0% for atorvastatin.
Sensitivity analyses suggested that lowering LDL-C by rosuvastatin could lead to regression of CAP with reduction of the plaque volume ranged from −0.153 mm 3 (SMD, 95% CI: −0.249~−0.056) when the arm of 2006 ASTEROID Ros was omitted to −0.178 mm 3 (SMD, 95% Table 5) .
Intensity of lowering LDL-C by different statins was shown in Table 6 . Rosuvastatin and atorvastatin could reduce LDL-C by more than 40%.
Discussion
Feature of this meta-analysis
This meta-analysis broke though the limit of single trial, and pooled arms together according to the levels of LDL-C at follow up in the arms, regardless of the measures of lowering LDL-C: treating arm (statins, ACAT inhibitor, CETP inhibitor, decreasing obesity drug, and glucose-lowering agents) and control arms (dietary restriction, moderate LDL-C lowering by statin); intensive and moderate LDL-C lowering. The volumes of CAP at follow up were compared with those at baseline in the same arms to evaluate the regression of the CAPs, this meta-analysis really reflected the change of the plaques volume with the change of LDL-C levels.
Our meta-analysis results indicated that intensive lowering LDL-C in group ≤70, >70 ≤ 100HP mg/dL (mean follow up LDL-C, mean duration of follow up: 60.6 mg/dL, 18.6 months; 77.8 mg/ dL, 17.4 months respectively), ≥30 < 40, ≥40 < 50 and ≥50% (mean LDL-C reducing, mean 
The importance of intensive lowing LDL-C on regression of CAP and LDL-C target of this meta-analysis
In the trials that evaluated the effects of LDL-C lowering on atheroma progression by IVUS, the effects varied with level of LDL-C at follow up. In group ≤70 mg, ≥30 < 40% and ≥40 < 50%, the LDL-C at baseline in most trials (including ESTABLISH [14] , REVERSAL [13] , JAPAN-ACS [12] , ASTEROID [37] , COSMOS [40] , trial by Kawasaki M [16] and by Nasu K [41]) were >120 mg. In ASTEROID [37] , COSMOS [40] , JAPAN-ACS [12] trial and fluvastatin arm of the trial by Nasu K [41] with respective the mean LDL-C level 60.8 mg, 82.9 mg, 81-84 mg and 98 mg (53.2%, 38.6%, 36% and 32.3% reduction of level of LDL-C) at follow up, it was showed that CAP could be regressed with intensive statin therapy. In ESTABLISH [14] and REVERSAL [13] , the mean reducing percent of LDL-C at follow up in the statin treatment arms were 44% and 46% respectively, the volumes of CAPs at follow up were not significantly decreased, compared with those in baseline. In the trails by Yokoyama M [15] and Kawasaki M [16] , mean reducing percentage of LDL-C at follow up was 35% for atorvastatin arm of the trial by Yokoyama M [15] , 32% for pravastatin arm of the trial by Kawasaki M [16] and 39% for atorvastatin arm of the trial by Kawasaki M [16] , the volume of CAPs at follow up were also not significantly decreased, compared with that at baseline. Pooled these arms with follow up LDL-C ≤70 mg or reducing >30% together, these meta-analysis showed that the CAPs could be regressed in group ≤70 mg, ≥30 < 40% and ≥40 < 50%. Because of publication bias in group ≥30 < 40% (Table 3) , the level of LDL-C in this group could not be recommended for regressing CAP. Based on the mean level and reducing percentage of LDL-C in group ≤70 mg and ≥40 < 50% (60.6 ± 3.5 mg, 48.8 ± 3.3%; 66.8 ± 8.0 mg, 45.4 ± 2.8%, in Table 4 ), the meta-analysis in group ≤70 mg and ≥40 < 50% suggested that for regressing CAP, LDL-C should be reduced by >45% or to a target level ≤ 66 mg/dL. In trials with 18-24 months of non-statin (ACAT inhibitor, decreasing obesity drugs and glucose-lowering agents) treatment, although the levels of LDL-C at follow up in some arms (ACTIVATE [22] , STRADIVARIUS [35] , PERISCOPE [36] , and A-PLUS [21] with daily 50 mg of avasimibe) were >70 ≤ 100 mg/dL, the LDL-C lowering percentage at follow up in the arms were below 30% because the levels of LDL-C at baseline were <95 mg/dL. In ILLUSTRATE trial [23] , after treatment with atorvastatin to reduce levels of LDL-C to less than 100 mg/dL, patients were randomly assigned to receive either atorvastatin monotherapy or atorvastatin plus 60 mg of torcetrapib daily. After 24 months, the reduction of LDL-C in both arms was <24% and the progression of CAP was not halted. In trial [34, 35] with statins treatment and baseline LDL-C < 110 mg, if the LDL-C lowering percentage at follow up were <24%, the CAP was also not regressed. The meta analysis with six arms in group >70 ≤ 100LP mg/dL and five arms in group >70 ≤ 100MP mg/dL did not show that only >70 ≤ 100 mg/dL of LDL-C level but <30% reduction at follow up could lead to regression of CAP, which further confirmed the importance of intensively lowering LDL-C in regression of CAP. Though LDL-C at follow up in some trials [13, 15, 16, 26, 27, 39] of LDL-C lowering by statins was >70 ≤ 100 mg/dL and reducing >30%, the CAP in the trials was also not regressed. Included eleven arms with baseline LDL-C > 130.0 mg/dL, follow up LDL-C >70 ≤ 100 mg/dL and LDL-C reducing >30% (in group >70 ≤ 100HP mg), this meta-analysis suggested that LDL-C reducing >40% or to target 77.8 mg could regress CAP ( Table 4 ). The metaanalysis in group >70 ≤ 100HP, >70 ≤ 100MP and >70 ≤ 100LP mg/dL indicated that LDL-C reducing percentage, not lowering absolute value of LDL-C at follow up, was important for regressing CAP. Although rosuvastatin, atorvastatin, pitavastatin, simvastatin, and fluvastatin in some trials could reduce LDL-C level to ≤100 mg or by 30%, the meta-analysis indicated that rosuvastatin, atorvastatin and pitavastatin (mean lowering LDL-C by 48.4%, 42.3% and 36.2% respectively) could regress the CAPs, and simvastatin with mean lowering LDL-C by 39.9% could not. The role of pitavastatin in regressing CAPs remains to be verified because the role was from only one RCT with 125 cases [12] . Pravastatin with mean lowering LDL-C by 24.6% could not regress the CAPs either. Fluvastatin with mean lowering LDL-C by 32.3% in the blinded endpoint trial with 40 patients can regress the CAP [41] , but meta-analysis indicated that fluvastatin could not regress the CAP. The reason that pravastatin and fluvastatin in this meta-analysis can not regress the CAPs might be attributed to their low-intensity of lowering LDL-C and low dosage which can not reduce LDL-C by >40%.
Taken all the results of meta-analysis together, it was recommended that LDL-C level should be reduced by >40% or to a target level < 78 mg/dL for regressing CAP. 
The difference of LDL-C target level between this meta-analysis and current guidelines
The patients included in this meta-analysis were coronary heart disease. According to 2004 the guideline of the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program [43] and 2011 ESC/EAS Guidelines for the management of dyslipidaemias [1] , this group of patients belongs to very high risk category, and the recommended targets of LDL-C should be less than 70 mg/dL or 30-40% reduction from baseline in [43] , mainly from the metaanalysis by Cholesterol Treatment Trialists' Collaborators [44] , which indicated that absolute benefit of LDL-C lowering related chiefly to the absolute reduction of LDL-C, and the risk reductions are proportional to the absolute LDL-C reductions, but the meta-analysis did not provide target level of LDL-C for the benefit in terms of cardiovascular disease reduction [44] . According to 2013 ACC/AHA blood cholesterol guideline [45] , this group of patients should be treated with highintensity statin (atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily), which was the intensity of statin suggested in this meta-analysis ( Table 6 ).
The results of our meta-analysis imply that the patients with CHD should be intensively treated with statins (rosuvastatin 33 mg or atorvastatin 60 mg daily) to reduce the level of LDL-C by >40% or to a target level <78 mg/dL for regressing CAP, which have a little different to the guidelines. These different targets level of LDL-C might be due to different observational index: cardiovascular events for both guidelines, CAP volume for this meta-analysis. Moreover, our target is directly from meta-analysis, the target of 2011 ESC/EAS Guidelines is from extrapolation of metaanalysis, not a direct data. Our meta-analysis revealed the relation between the regression of coronary artery disease and LDL-C level from the view of pathological anatomy. Published meta-analysis [17, 18] about CAP by IVUS did not review the relationship between LDL-C level and CAP.
Study limitation
The results of this analysis were obtained by pooling data from twenty clinical trials. As with any metaanalysis, this study has some limitations. Firstly, though no publication bias was observed by Egger's test there may be a potential of publication bias because only published data were included. Secondly, the methodology used for measurement of coronary atheroma might not be the same in the studies. The plaques volume may be calculated from slices with 1 mm apart for a length of 10 mm vessel in some trials [13, 15, 22, 23, [27] [28] [29] 37] , or 0.1-0.3 mm-apart for a length of 10-50 mm vessel in other trials [12, 21, 33, 39, 40] , which might affect accuracy of plaque measurement. There were some differences in selecting plaque: some trials assessed the plaque in nonculprit vessel, while others assessed non-culprit plaque in a culprit vessel [12, 14, 34] , which assured the plaque was stable. Our study focus on target plaque change, i.e. plaque regression or progression, those differences in measurements and plaque selection did not affect the change of the target plaque with LDL-C levels. So, it has little effect on homogeneous of studies, and this detection bias was very much limited from values of P in χ 2 test and I 2 in each group. Thirdly, follow up duration might have some effects of the changes of CAP. Fourthly, other cardiovascular risk factors but LDL-C levels, for example, demographic characteristics such as age, gender and ethnicity, might also affect the effect of LDL-C on CAP, and the effects of these factors on CAP remain to be investigated in future.
Implication for practice
This meta-analysis investigated the effect of reduction of LDL-C only on the regression of the plaque, not on reduction of cardiovascular events. In fact, all the included trial have no the data about death because only the alive have IVUS data at follow up. But in four-year of the OLIVUS-Ex [46] , it was found that patients with annual atheroma progression had more adverse cardio-and cerebrovascular events than the rest of the population. A meta-analysis [47] included 7864 CAD patients showed that rates of plaque volume regression were significantly associated with the incidence of MI or revascularization, and it was concluded that regression of atherosclerotic coronary plaque volume in stable CAD patients may represent a surrogate for myocardial infarction and repeat revascularization. Plaque in CAD, as blood pressure level in hypertension, is not major adverse cardiac events, but does be an important surrogate. Therefore, the conclusion of this meta-analysis not only applies to guide LDL-C lowering therapy for regressing CAP, may also apply to guide LDL-C lowering therapy for reducing major adverse cardio-and cerebrovascular events. Furthermore, high level of LDL-C plays a crucial role in the formation of atherosclerotic plaque, but LDL-C level is not unique risk factor for atherosclerotic plaque. Hypertension is another important risk factor for the formation of plaque [48, 49] . Smoking cessation, administrating β-blockers, anti-hypertension therapy might play some role in slowing progression of CAP [48, [50] [51] [52] . The trend of CAP regression in group <0% might attribute to these non-LDL-C reducing factors.
Conclusions
Atherosclerotic plaque extension and disruption are basic mechanism of atherosclerotic cardio-and cerebrovascular disease. Stabling and regressing atherosclerotic plaque play an important role in preventing cardio-and cerebrovascular disease. Pooled the twenty trials with CAP detected by gold standard: IVUS, this systemic review demonstrated that intensive lowering LDL-C (rosuvastatin mean 33 mg daily and atorvastatin mean 60 mg daily) with >17 months of duration could lead to the regression of coronary atherosclerotic plaque, LDL-C level should be reduced by >40% or to a target level < 78 mg/dL for regressing CAP.
